HOME >> MEDICINE >> NEWS
Leukemia drug breakthrough study in New England Journal of Medicine

Tampa, FL (Feb. 9, 2005) - Alan List, M.D., leader of the Hematologic Malignancies Program at the H. Lee Moffitt Cancer Center & Research Institute, recently conducted a phase I/II trial of the experimental drug Revlimid showing promise as an innovative way to treat patients with myelodysplastic syndrome (MDS), a form of pre-leukemia. Given in pill form, Revlimid simultaneously blocks the growth of new blood vessels that nourish tumors (anti-angiogenesis) and stimulates the immune system to fight cancer cells. The study is reported in the Feb.10 issue of the New England Journal of Medicine.

Nearly 90 percent of MDS patients are anemic and require regular transfusions of red cells. In this study, 91 percent of the MDS patients with a chromosome abnormality named 5q minus syndrome became transfusion independent. The defective 5q chromosome abnormality may be linked to other serious cancers, including leukemias and small cell lung cancer.

In another finding of the same study, all the patients with the 5q deletion who became transfusion independent also went into cytogenetic remission, meaning that the chromosome abnormality disappeared.

List, a professor of interdisciplinary oncology at the University of South Florida, initially developed the phase I clinical trial of Revlimid for treatment of MDS following his laboratory observations that the agent improved the growth of red blood cell precursors from MDS bone marrow. Celgene will submit the seminal findings of List's phase I trial - along with data from two recent confirmatory phase II clinical trials performed nationwide involving more than 350 patients with red blood cell transfusion-dependent MDS - to the U.S. Food and Drug Administration in a new drug application (NDA) for Revlimid as an innovative approach to treat the anemia of MDS patients with the 5q minus deletion.

In 2001, the National Cancer Institute awarded Moffitt the status of a Comprehensive Cancer Center in r
'"/>

Contact: Andrea Brunais
MediaRelations@moffitt.usf.edu
813-632-1478
University of South Florida Health
9-Feb-2005


Page: 1 2

Related medicine news :

1. Leukemia patients survive with stem cell transplant
2. Breakthrough New Therapy Uses Antibody-Targeted Chemotherapy To Fight Leukemia
3. Maxim Phase II Clinical Trial Highlights Substantial Increase In Leukemia-FreeSurvival For Acute Myelogenous Leukemia Patients
4. Promising New Drug Uses Antibody Targeted Chemotherapy To Fight Leukemia
5. University of Kentucky Markey Cancer Center Researchers Awarded Grant To Fight Leukemia Recurrence
6. OHSU Scientists Begin Human Trials Of A Drug Aimed At The Underlying Cause Of Chronic Myelogenous Leukemia
7. Fertilization Protein Structure To AID in Leukemia Treatment
8. International gathering of experts to share retinoblastoma breakthroughs
9. Consumers to benefit from organic potato breakthrough
10. Biotech breakthrough in islet cell replacement for type 1 diabetes
11. 4 out of 5 eligible patients missing opportunity to benefit from latest HIV breakthrough

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... ... September 03, 2020 , ... International Dark-Sky ... WALI wireless parking lot controller. This advanced LED wireless dimming controller, along with ... and protecting the night sky against light pollution. Leo Smith, the Northeast Regional ...
(Date:9/1/2020)... (PRWEB) , ... September 01, 2020 , ... As fall ... side”, the Cohn Health Institute has taken this time to expand and ... of its 30th Anniversary, the Cohn Health Institute will be relaunching its brand new ...
(Date:8/31/2020)... ... August 31, 2020 , ... Ocean Springs, Mississippi-based pharmaceutical ... medical first responders across the United States. Since the start of the global ... (PPE) medical centers , hospitals , firefighters , and ...
(Date:8/31/2020)... ... ... pandemic and topsy-turvy economic outlook continues to put financial strain on many of us, so ... fat from our monthly expenses and put more into savings, if possible. , “That’s a ... financial safety net in place in case something were to happen to you,” says Lee ...
(Date:8/29/2020)... MONTREAL (PRWEB) , ... August 29, 2020 , ... When ... - perhaps with greater ease than most people would. Rather than become melancholic, however, ... yet deep advice on achieving one’s dreams. Randy Pausch took a negative situation and ...
Breaking Medicine News(10 mins):
(Date:9/1/2020)... , ... September 01, 2020 , ... ... technologies, will host the Agilent Science and Technology Virtual Symposium 2020 (ASTVS ... symposium, Agilent will open a suite of Live webinars and Networking sessions, with ...
(Date:9/1/2020)... ... September 01, 2020 , ... While coronavirus cases continue to increase across ... and community organizations remain closed. Because about 80% of blood donations are made at ... blood donors and blood drive hosts to ensure blood products are readily available for ...
(Date:8/31/2020)... ... August 31, 2020 , ... Welltech1, the ... that they have invested $400,000 in PopBase, one of two start-ups that beat ... Global Wellness Institute (GWI). , The competition was part of the GWI’s ...
Breaking Medicine Technology:
Cached News: